We are pleased to announce that Ulrich Zimmermann has decided to take over responsibility as Managing Director of BIT Analytical Instruments GmbH and CFO Global of BIT Group effective on April 15, 2021.
BIT Hematology is specialized in designing, developing, and manufacturing hematology systems (instruments and exclusive reagents) for the low and mid-volume markets.
We are pleased to announce the appointment of Dr. Michael Bartels to the position of CEO Global of BIT Group as of August 1, 2020. Michael brings to the company more than 25 years of sales and leadership experience for HealthCare solutions.
The regulatory and quality requirements in the IVD market are stringent and impact every step throughout a product’s life cycle.
We are pleased to inform you that BIT Group USA, Inc. will be consolidated into one location in Irvine/ CA. This will allow us to realize synergies and to expand our capabilities to better serve your growing needs.
In-Vitro Diagnostics (IVD) instruments are complex systems that require a transdisciplinary engineering approach that includes all disciplines, such as mechanical, electrical, fluidical, optical, software, as well as biological and chemical components.
Design for Manufacturing (DFM) is the process of designing parts, components, or products for ease of manufacturing with an end goal of making a better product in a cost-efficient way.
A note from Messer (BIT’s parent company) on their activities in response to the Coronavirus
Contract manufacturing is in BIT’s DNA. Founded in 1976, BIT began the journey as a medical device contract manufacturer in Frankfurt, Germany.
With just over 25 years’ experience in molecular automation development and manufacturing, BIT is excited to be exhibiting at AMP’s 25th-anniversary meeting.